<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fenofibrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fenofibrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fenofibrate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="91585" href="/d/html/91585.html" rel="external">see "Fenofibrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49638570"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Antara [DSC];</li>
<li>Fenoglide;</li>
<li>Fibricor;</li>
<li>Lipofen;</li>
<li>Tricor;</li>
<li>Triglide [DSC];</li>
<li>Trilipix</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871667"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Feno-Micro;</li>
<li>AA-Feno-Super;</li>
<li>APO-Fenofibrate [DSC];</li>
<li>Feno-Micro-200 [DSC];</li>
<li>Fenofibrate Micro;</li>
<li>Fenomax [DSC];</li>
<li>Lipidil EZ;</li>
<li>Lipidil Supra;</li>
<li>MINT-Fenofibrate E [DSC];</li>
<li>PMS-Fenofibrate [DSC];</li>
<li>SANDOZ Fenofibrate E;</li>
<li>SANDOZ Fenofibrate S [DSC];</li>
<li>TARO-Fenofibrate E</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22370293"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Fibric Acid</li></ul></div>
<div class="block doa drugH1Div" id="F22370331"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5fe11c5-5429-4488-93aa-98e687a47477">Hypertriglyceridemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> All patients should receive general measures (ie, address modifiable causes, manage atherosclerotic cardiovascular disease [ASCVD] risk, implement lifestyle modification [eg, dietary changes, reduction of alcohol consumption]) and optimal low-density lipoprotein–lowering therapy for 4 to 12 weeks before considering triglyceride-lowering therapy. For patients whose triglycerides remain ≥500 mg/dL and who do not warrant icosapent ethyl for additional ASCVD risk reduction, either a fibrate (fenofibrate preferred) or any prescription strength omega-3 fatty acid (including icosapent ethyl) is reasonable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">Fenofibrate and Derivatives <b>Hypertriglyceridemia Dosing</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Formulation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Products</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Available strengths</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dosage range</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Maximum dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Capsule, choline fenofibrate</p></td>
<td align="center">
<p style="text-indent:0em;">Trilipix and generics</p></td>
<td align="center">
<p style="text-indent:0em;">45 mg, 135 mg</p></td>
<td align="center">
<p style="text-indent:0em;">45 to 135 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">135 mg/day</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Capsule, micronized</p></td>
<td align="center">
<p style="text-indent:0em;">Antara and generics</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg, 90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">30 to 90 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Generics</p></td>
<td align="center">
<p style="text-indent:0em;">43 mg, 130 mg</p></td>
<td align="center">
<p style="text-indent:0em;">43 to 130 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">130 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Generics</p></td>
<td align="center">
<p style="text-indent:0em;">67 mg, 134 mg, 200 mg</p></td>
<td align="center">
<p style="text-indent:0em;">67 to 200 mg once daily with food</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Capsule, nonmicronized</p></td>
<td align="center">
<p style="text-indent:0em;">Lipofen and generics</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg, 150 mg</p></td>
<td align="center">
<p style="text-indent:0em;">50 to 150 mg once daily with food</p></td>
<td align="center">
<p style="text-indent:0em;">150 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Tablet, fenofibric acid</p></td>
<td align="center">
<p style="text-indent:0em;">Fibricor and generics</p></td>
<td align="center">
<p style="text-indent:0em;">35 mg, 105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">35 to 105 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Tablet, microcoated</p></td>
<td align="center">
<p style="text-indent:0em;">Lipidil Supra [Canadian product] and generics</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg, 160 mg</p></td>
<td align="center">
<p style="text-indent:0em;">160 to 200 mg once daily with food</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg/day</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Tablet, nanocrystal</p></td>
<td align="center">
<p style="text-indent:0em;">TriCor and generics</p></td>
<td align="center">
<p style="text-indent:0em;">48 mg, 145 mg</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 145 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">145 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Lipidil EZ [Canadian product] and generics</p></td>
<td align="center">
<p style="text-indent:0em;">48 mg, 145 mg</p></td>
<td align="center">
<p style="text-indent:0em;">145 mg once daily with or without food</p></td>
<td align="center">
<p style="text-indent:0em;">145 mg/day</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Tablet, nonmicronized</p></td>
<td align="center">
<p style="text-indent:0em;">Fenoglide and generics</p></td>
<td align="center">
<p style="text-indent:0em;">40 mg, 120 mg</p></td>
<td align="center">
<p style="text-indent:0em;">40 to 120 mg once daily with food</p></td>
<td align="center">
<p style="text-indent:0em;">120 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Generics</p></td>
<td align="center">
<p style="text-indent:0em;">54 mg, 160 mg</p></td>
<td align="center">
<p style="text-indent:0em;">54 to 160 mg once daily with food</p></td>
<td align="center">
<p style="text-indent:0em;">160 mg/day</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991115"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Fenofibrate use has been associated with reversible elevations in serum creatinine, although the clinical significance is unknown. If creatinine levels are significantly elevated with fibrate therapy and no other clinically relevant cause is evident, then interruption of therapy may be warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Multiple formulations available. The following recommendations are considered applicable to all formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 to 80 mL/minute: Use lowest available tablet strength (if a formulation is not available in a strength that is ≤67 mg, then an alternate formulation should be used); do not titrate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤30 mL/minute: Use contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7110477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7110477'])">Ref</a></span>): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be dialyzable: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Not likely to be significantly removed; avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Not likely to be significantly removed; avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988430"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated. Regular monitoring of LFTs is required; drug-induced liver injury has been reported in postmarketing studies with some formulations resulting in liver transplantation or death. Discontinue therapy in patients with signs/symptoms of liver injury or whose enzyme levels persist above 3 times the ULN or accompanied by elevated bilirubin. Do not restart if there is no other explanation for liver injury.</p></div>
<div class="block dot drugH1Div" id="F22549100"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Cholelithiasis:</i> Discontinue if gallstones are found upon gallbladder studies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>CPK elevation, myopathy, and/or myositis:</i> Discontinue therapy if the patient develops markedly elevated CPK concentrations or if myopathy/myositis is suspected or diagnosed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>HDL-C reductions:</i> Permanently discontinue therapy if HDL-C becomes severely depressed; monitor HDL-C concentrations until returned to baseline.</p></div>
<div class="block doe drugH1Div" id="F22370332"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Initial: Adjust dosage based on kidney function; additional product-specific recommendations for initial dose:</p>
<p style="text-indent:-2em;margin-left:4em;">Fenofibrate, micronized capsule (available strengths: 67 mg, 134 mg, 200 mg): <b>Oral:</b> 67 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Lipidil EZ [Canadian product] (available strengths: 48 mg, 145 mg): <b>Oral:</b> 48 mg once daily.</p></div>
<div class="block arsc drugH1Div" id="F56362810"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased serum aminotransferases (<b>increased serum alanine aminotransferase</b> (ALT) and <b>increased serum aspartate aminotransferase</b>) and <b>hepatotoxicity</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16437706','lexi-content-ref-34325660','lexi-content-ref-16937543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16437706','lexi-content-ref-34325660','lexi-content-ref-16937543'])">Ref</a></span>). Liver injury has ranged from <b>hepatocellular hepatitis</b> to <b>cholestatic hepatitis</b> or mixed <b>hepatitis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413'])">Ref</a></span>). Acute cholestatic hepatitis, <b>hepatic cirrhosis</b>, and hepatitis with autoimmune features have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413','lexi-content-ref-15745090','lexi-content-ref-19744016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413','lexi-content-ref-15745090','lexi-content-ref-19744016'])">Ref</a></span>). Increased serum aminotransferases are usually mild and transient but may require drug discontinuation if levels persist above 3 times the upper limit of normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413'])">Ref</a></span>); ALT elevations normalize within 2 to 4 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15745090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15745090'])">Ref</a></span>). Serum aminotransferase levels have been reported to return to normal within 12 days after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16437706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16437706'])">Ref</a></span>). Levels have also been reported to remain elevated 21 months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16937543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16937543'])">Ref</a></span>). In some cases, patients may have progressive cholestasis and hepatic failure that may require liver transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413'])">Ref</a></span>). There is an increased risk of liver toxicity with fenofibrate compared to gemfibrozil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18157972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18157972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown: Non–dose-related; possibly immune-mediated response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; duration of therapy prior to onset of hepatotoxicity ranges from 1 to 8 weeks to several months but, may occur earlier (eg, after 2 days) or after years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29119413','lexi-content-ref-15745090','lexi-content-ref-16437706','lexi-content-ref-19744016','lexi-content-ref-34325660','lexi-content-ref-31518450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29119413','lexi-content-ref-15745090','lexi-content-ref-16437706','lexi-content-ref-19744016','lexi-content-ref-34325660','lexi-content-ref-31518450'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-A*33:01 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28043905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28043905'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of delayed hypersensitivity reactions, ranging from mild maculopapular <b>skin rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22812208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22812208'])">Ref</a></span>) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome</b> and<b> toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30666843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30666843'])">Ref</a></span>), <b>drug rash with eosinophilia and systemic symptoms</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30666843','lexi-content-ref-25269143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30666843','lexi-content-ref-25269143'])">Ref</a></span>), and <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Morais.1','lexi-content-ref-26581932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Morais.1','lexi-content-ref-26581932'])">Ref</a></span>) may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic (ie, T-cell mediated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; maculopapular rash may occur within 1 to 2 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22812208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22812208'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between fenofibrate and bezafibrate, but not gemfibrozil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22812208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22812208'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myopathy/rhabdomyolysis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myopathy</b> and <b>rhabdomyolysis</b> have been reported with fibrates, including fenofibrate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275'])">Ref</a></span>) when used as monotherapy or in combination with other agents (usually a statin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20811485','lexi-content-ref-22019952','lexi-content-ref-15941707','lexi-content-ref-21960954','lexi-content-ref-18520113','lexi-content-ref-19756555','lexi-content-ref-32481339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20811485','lexi-content-ref-22019952','lexi-content-ref-15941707','lexi-content-ref-21960954','lexi-content-ref-18520113','lexi-content-ref-19756555','lexi-content-ref-32481339'])">Ref</a></span>). There is an increased risk of myopathy and rhabdomyolysis with gemfibrozil compared to fenofibrate, especially when used in combination with a statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15464682','lexi-content-ref-17368275','lexi-content-ref-15619408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15464682','lexi-content-ref-17368275','lexi-content-ref-15619408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; may exacerbate latent preexisting mitochondrial myopathies, accelerate normal physiologic changes in skeletal muscle associated with aging, or may have a direct toxic action on muscle cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; rhabdomyolysis has occurred from 3 days to 3 years (average time was 17.5 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32481339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32481339'])">Ref</a></span>), with more rapid onset following rechallenges (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23833382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23833382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diabetes, kidney failure, and/or hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275','lexi-content-ref-22019952','lexi-content-ref-29620657','lexi-content-ref-19756555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275','lexi-content-ref-22019952','lexi-content-ref-29620657','lexi-content-ref-19756555'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21917557','lexi-content-ref-17368275','lexi-content-ref-30575126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21917557','lexi-content-ref-17368275','lexi-content-ref-30575126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275','lexi-content-ref-19756555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275','lexi-content-ref-19756555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Photosensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin photosensitivity </b>may result in various cutaneous eruptions, including erythematous, eczematous, lichenoid, papulovesicular, and sunburn-like rashes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32540810','lexi-content-ref-29282398','lexi-content-ref-28317179','lexi-content-ref-30911397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32540810','lexi-content-ref-29282398','lexi-content-ref-28317179','lexi-content-ref-30911397'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic. May be due to the photoexcited benzophenone structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28317179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28317179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; from 3 days to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28317179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28317179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-photosensitization between fenofibrate and ketoprofen due to structural similarities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28474616','lexi-content-ref-1430357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28474616','lexi-content-ref-1430357'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum creatinine</b> has occurred with fibrates, including fenofibrate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275','lexi-content-ref-28775808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275','lexi-content-ref-28775808'])">Ref</a></span>). In some patients, increases in serum creatinine may not result in significant changes in glomerular filtration rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275'])">Ref</a></span>). <b>Acute kidney injury</b> has also been reported, usually in association with rhabdomyolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20486848','lexi-content-ref-17994463','lexi-content-ref-18520113','lexi-content-ref-32481339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20486848','lexi-content-ref-17994463','lexi-content-ref-18520113','lexi-content-ref-32481339'])">Ref</a></span>). Increase in serum creatinine is usually reversible with discontinuation (usually within 51 days) or in some patients with continued use of fenofibrate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22264570','lexi-content-ref-22432114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22264570','lexi-content-ref-22432114'])">Ref</a></span>). There is an increased risk with fenofibrate compared to gemfibrozil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368275'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related. Unknown; may impair production of vasodilatory prostaglandins due to activation of peroxisome proliferators-activated receptors. An induced elevation of the metabolic production rate of creatinine may occur in patients with isolated increases in serum creatinine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23820458','lexi-content-ref-17368275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23820458','lexi-content-ref-17368275'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increase in serum creatinine is usually observed within 20 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33704429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33704429'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose fenofibrate (≥145 mg/day), especially in patients with underlying kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22264570','lexi-content-ref-23480615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22264570','lexi-content-ref-23480615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment, concurrent diabetes, patients with kidney transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23820458','lexi-content-ref-17368275','lexi-content-ref-32582345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23820458','lexi-content-ref-17368275','lexi-content-ref-32582345'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23820458','lexi-content-ref-23480615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23820458','lexi-content-ref-23480615'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F22370307"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hepatic: Increased serum alanine aminotransferase (≥3 x ULN: ≤13%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span>, increased serum aspartate aminotransferase (≥3 x ULN: ≤13%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-aspartate-aminotransferase')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Aspartate Aminotransferase</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption>
<b>Fenofibrate and Derivatives: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenofibrate and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenofibrate and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Doses equivalent to 96 to 145 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT or AST elevations ≥3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Doses equivalent to 96 to 145 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">365</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT and AST elevations &gt;3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Doses equivalent to ≤48 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT or AST elevations ≥3 x ULN</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-increased-serum-aspartate-aminotransferase" rules="all">
<caption>
<b>Fenofibrate and Derivatives: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fenofibrate and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fenofibrate and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Doses equivalent to 96 to 145 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT or AST elevations ≥3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">365</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT and AST elevations &gt;3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Doses equivalent to ≤48 mg daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ALT or AST elevations ≥3 x ULN</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1%), urticaria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), constipation (2%), diarrhea (≥3%), dyspepsia (≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≥3%), pain (≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥3%), increased creatine phosphokinase in blood specimen (3%), limb pain (≥3%), myalgia (≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (≥3%), rhinitis (2%), sinusitis (≥3%), upper respiratory tract infection (≥3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Renal: Increased serum creatinine (Kim 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Morias 2008), skin photosensitivity (Tsai 2017), Stevens-Johnson syndrome (Kang 2019), toxic epidermal necrolysis (Kang 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (can be severe) (Mymin 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Chung 2018; Douros 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, thrombocytopenia (Agapakis 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Hajdu 2009), hepatic cirrhosis (Ahmed 2005), hepatitis (including autoimmune and mixed) (Ahmad 2017), hepatocellular hepatitis (Ahmad 2017), hepatotoxicity (including acute and severe) (Ma 2020), increased serum bilirubin (He 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Kang 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (Rabasa-Lhoret 2001), muscle spasm, myopathy, rhabdomyolysis (Zhou 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Zhou 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease</p></div>
<div class="block coi drugH1Div" id="F22370304"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fenofibrate or fenofibric acid or any component of the formulation; active liver disease, including primary biliary cirrhosis and unexplained, persistent liver function abnormality; severe kidney impairment or end-stage kidney disease, including those receiving dialysis; preexisting gallbladder disease; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen; chronic or acute pancreatitis; patients &lt;18 years of age; coadministration with HMG-CoA reductase inhibitors in patients with a predisposition for myopathy; allergy to soya lecithin, peanut or arachis oil, or related products (tablet formulations only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F22370305"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cholelithiasis: May cause cholelithiasis; discontinue if gallstones are found upon gallbladder studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• HDL cholesterol: A paradoxical, severe, and reversible decrease in HDL-C (as low as 2 mg/dL) with a simultaneous decrease in apolipoprotein A1 has been reported within 2 weeks to years after initiation of fibrate therapy; clinical significance unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: May cause mild to moderate decreases in hemoglobin, hematocrit, and WBC upon initiation of therapy, which usually stabilizes with long-term therapy. Agranulocytosis and thrombocytopenia have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Pancreatitis has been reported with fenofibrate use; may be secondary to a failure of efficacy in patients with severe hypertriglyceridemia, medication side effect, or due to biliary tract stone or sludge formation from bile duct obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Venous thromboembolism: Use has been associated with pulmonary embolism and deep vein thrombosis. Use with caution in patients with risk factors for venous thromboembolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Fibric acid derivatives have not demonstrated significant efficacy in altering cardiovascular disease mortality in major clinical studies. In two large randomized controlled clinical trials, neither fenofibrate monotherapy (Keech 2005) nor the addition of fenofibrate to simvastatin (ACCORD Study Group 2010) compared to placebo were shown to reduce cardiovascular disease morbidity and mortality in patients with type 2 diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Contraindicated in patients with active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with mild to moderate kidney impairment; dosage adjustment required. Contraindicated in patients with severe kidney impairment, including those receiving dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• HMG-CoA reductase inhibitors: Use caution with HMG-CoA reductase inhibitors. No incremental benefit of combination therapy on cardiovascular morbidity and mortality over statin monotherapy has been established. In combination with HMG-CoA reductase inhibitors, fenofibrate is generally regarded as safer than gemfibrozil due to limited pharmacokinetic interaction with statins. Fenofibrate may be considered in patients on low- or moderate-intensity statin therapy (ie, statin therapy intended to lower LDL-C by &lt;30% or ~30% to 50%, respectively) only if the benefits from atherosclerotic cardiovascular disease risk reduction or triglyceride lowering when triglycerides are &gt;500 mg/dL, outweigh the potential risk for adverse effects (ACC/AHA [Stone 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adults; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Peanut or arachis oil: Some products may contain peanut or arachis oil; use is contraindicated in patients with a peanut or arachis allergy for applicable formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Soya lecithin: Some products may contain soya lecithin; use is contraindicated in patients with a soya lecithin allergy for applicable formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Optimal response: Therapy should be withdrawn if an adequate response is not obtained after 2 to 3 months of therapy at the maximal daily dose.</p></div>
<div class="block dosfc drugH1Div" id="F22370348"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Micronized formulations: Antara.</p>
<p style="text-indent:-2em;margin-left:2em;">Strength of choline fenofibrate products are expressed in terms of fenofibric acid.</p></div>
<div class="block foc drugH1Div" id="F49638571"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as fenofibrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antara: 30 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antara: 90 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipofen: 50 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipofen: 150 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipofen: 150 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg [DSC], 43 mg, 50 mg, 67 mg, 90 mg [DSC], 130 mg, 134 mg, 150 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as choline fenofibrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trilipix: 45 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trilipix: 135 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 45 mg, 135 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fenofibrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fenoglide: 40 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tricor: 48 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tricor: 145 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triglide: 160 mg [DSC] [contains egg phospholipids (egg lecithin)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 48 mg, 54 mg, 120 mg, 145 mg, 160 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fenofibric acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fibricor: 35 mg, 105 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 35 mg, 105 mg</p></div>
<div class="block geq drugH1Div" id="F49638569"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F22370351"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Trilipix Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $3.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">135 mg (per each): $10.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fenofibrate Micronized Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">43 mg (per each): $2.27 - $2.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">67 mg (per each): $0.27 - $1.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">130 mg (per each): $6.83 - $6.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">134 mg (per each): $0.45 - $1.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.79 - $3.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fenofibrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $3.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $7.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lipofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $12.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fenofibrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $10.44 - $13.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">48 mg (per each): $0.43 - $1.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">54 mg (per each): $0.30 - $0.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $31.33 - $40.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">145 mg (per each): $0.78 - $5.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $0.61 - $2.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fenofibric Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $11.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg (per each): $23.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fenoglide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $14.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $44.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fibricor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $19.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg (per each): $39.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tricor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">48 mg (per each): $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">145 mg (per each): $1.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871668"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fenomax: 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as fenofibrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 67 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fenofibrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipidil EZ: 48 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipidil EZ: 145 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipidil Supra: 160 mg [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 48 mg, 145 mg, 160 mg</p></div>
<div class="block adm drugH1Div" id="F22370337"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Antara, fenofibrate (micronized), Fibricor, Lipidil EZ [Canadian product], TriCor, Triglide, Trilipix: Administer with or without food. Swallow whole; do not open (capsules), crush, dissolve, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Fenoglide, Lipofen, Lipidil Supra [Canadian product]: Administer with meals. Swallow whole; do not open (capsules), crush, dissolve, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release capsules should not be opened. Switch to a formulation that is not delayed release at the nearest possible dose in a tablet or capsule and either crush or open as appropriate.</p></div>
<div class="block use drugH1Div" id="F22370297"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertriglyceridemia:</b> Adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).</p></div>
<div class="block mst drugH1Div" id="F22370285"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fibricor may be confused with Tricor</p>
<p style="text-indent:-2em;margin-left:4em;">TriCor may be confused with Fibricor, Tracleer</p>
<p style="text-indent:-2em;margin-left:4em;">TriLipix may be confused with Trileptal, TriLyte</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F22370312"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F22370313"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of Fibric Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezetimibe: Fenofibrate and Derivatives may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fenofibrate and Derivatives may increase the serum concentration of Ezetimibe. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C9 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Fenofibrate and Derivatives may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May enhance the nephrotoxic effect of Fenofibrate and Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider reducing the oral anticoagulant dose by 25% to 33% when initiating a fibric acid derivative. Monitor for toxic or reduced anticoagulant effects if a fibric acid derivative is initiated/dose increased, or discontinued/dose decreased, respectively.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Fenofibrate and Derivatives may enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.  Management: Monitor for signs and symptoms of bleeding, and increase INR monitoring in patients taking warfarin who are initiated on fenofibrate derivatives. Warfarin dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F22549098"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Antara (micronized):</i> When administered under fasted conditions or with a low-fat meal, the extent of absorption and the time to peak did not change; however peak concentrations were increased in the presence of a low-fat meal. When administered with a high fat meal, a 26% increase in the AUC and 108% increase in the peak concentration were seen in comparison to the fasted state. Management: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Fenoglide:</i> When administered with a high-fat meal, the peak concentration was increased by 44% as compared to fasting conditions. Management: Administer with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Fibricor:</i> When administered with a high-fat meal, the peak concentration was decreased by ~35% while AUC remained unchanged as compared to fasting conditions. Management: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Lipidil EZ [Canadian product]:</i> Bioavailability was not significantly different when administered under fasting and nonfasting conditions. Management: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Lipidil Supra [Canadian product]:</i> In general, fenofibrate absorption is low and variable when administered under fasting conditions; absorption is increased when administered with food. Management: Administer with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Lipofen:</i> When administered with a low-fat and high-fat meal, the extent of absorption is increased by ~25% and ~58%, respectively, as compared to fasting conditions. Management: Administer with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>TriCor:</i> Peak concentrations and AUC were not significantly different when a single dose was administered under fasting and nonfasting conditions. Management: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Triglide:</i> When administered with food, the rate of absorption was increased ~55% as compared to fasting conditions; the AUC remained unchanged. Management: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Trilipix:</i> Peak concentrations and AUC were not significantly different when a single dose was administered under fasting and nonfasting conditions. Management: Administer with or without food.</p></div>
<div class="block pri drugH1Div" id="F22370301"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Triglyceride and lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. In patients who are pregnant who develop severe hypertriglyceridemia and are at risk for pancreatitis, use of fenofibrate beginning in the second trimester is one intervention that may be considered. Agents other than fenofibrate should be used for hypercholesterolemia (Avis 2009; Berglund 2012; Jacobson 2015; Wong 2015).</p></div>
<div class="block brc drugH1Div" id="F22370303"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if fenofibrate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Lipids are a normal component of breast milk and the fatty acid component is required for normal infant neurologic development. Maternal diet, as well as other factors, may influence the fatty acid composition (Innis 2014). When treatment for severe hypertriglyceridemia in breastfeeding patients at risk for pancreatitis is needed, therapy with fenofibrate may be considered (Jacobson 2015). When treatment is needed for other indications, agents other than fenofibrate are preferred (Jacobson 2015; NICE 2008). Due to the potential for serious adverse reactions in the breastfed infant (such as disrupting lipid metabolism), breastfeeding is contraindicated by the manufacturer; some products specifically do not recommend breastfeeding until 5 days after the last dose.</p></div>
<div class="block dic drugH1Div" id="F22370336"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Antara, Fibricor, Lipidil EZ [Canadian product], TriCor, Triglide, Trilipix: May be taken with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Fenoglide, Lipidil Supra [Canadian product], Lipofen: Take with meals.</p></div>
<div class="block mop drugH1Div" id="F22370339"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic blood counts during first year of therapy. Monitor lipid profile periodically, including HDL-C within a few months of initiation of therapy. Monitor LFTs at baseline and periodically during therapy. Monitor kidney function in patients with kidney impairment or in those at increased risk for developing kidney impairment. Monitor for signs/symptoms of myopathy, myositis, or rhabdomyolysis (eg, CPK elevation; muscle pain, tenderness, weakness, especially if accompanied with malaise or fever; brown urine).</p></div>
<div class="block pha drugH1Div" id="F22370318"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fenofibric acid, an agonist for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha (PPAR-alpha), downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) and upregulates the synthesis of apolipoprotein A-I, fatty acid transport protein, and lipoprotein lipase resulting in an increase in VLDL catabolism, fatty acid oxidation, and elimination of triglyceride-rich particles; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30% to 60%; modest increase in HDL occurs in some hypertriglyceridemic patients.</p></div>
<div class="block phk drugH1Div" id="F22370320"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Increased when taken with meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to most tissues.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Fenofibrate is metabolized in the tissue and plasma via esterases to the active form, fenofibric acid; fenofibric acid then undergoes inactivation by glucuronidation hepatically or renally.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Fenofibric acid: ~81%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Fenofibric acid: Mean: 20 hours (range: 10 to 35 hours); half-life prolonged in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% as metabolites); feces (25%); hemodialysis has no effect on removal of fenofibric acid from plasma.</p></div>
<div class="block phksp drugH1Div" id="F51192543"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe kidney impairment (CrCl ≤30 mL/minute), clearance of fenofibrate is greatly reduced. Clearance is reduced to a lesser degree in patients with mild to moderate kidney impairment (CrCl 30 to 80 mL/minute).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49626998"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fenolip 145 | Fenotab | Lipanthyl | Lipicard | Supralip | Trinex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Controlip | Craveril | Daunlip | Fenobrate | Fenofibrato richet | Fenosane | Gadolip | Ilfen | Lipidil | Lipo plus | Lipoplasmin | Liptuin | Minuslip | Procetoken | Procetoken xr | Qualecon | Sclerofin u.d. | Segren | Templaris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Apteor | Fenolip | Lipanthyl supra | Lipcor | Lipsin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo fenofibrate | Btc fenofibrate | Fenocol | Fenofibrate cipla | Fenofibrate mylan | Fenofibrate sandoz | Fenofibrate sun | Fenofibrate viatris | Lipidil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Fenatrol | Fenobate | Fenocap | Fenocol | Fenolid | Fenorat | Lipidof | Lipired | Nofiate | Noficon | Tigirate | Trigent</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docfenofi | Fenofibrate bexal | Fenofibrate eurogenerics | Fenofibrate merck-generics | Fenofibrate mylan | Fenofibrate sandoz | Fenofibrate teva generics belgium | Fenofitop | Fenogal | Lipanthyl | Lipanthylnano</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Feno tg | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrat | Fibranor | Lipanthyl | Lipanthyl supra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fenobraty | Fenofibrato | Fenofibrato micronizado | Hipofithy | Lanpexio | Lipanon | Lipidil | Lipobrato | Reducofen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lipanthyl</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Feno tg | Fenothyl | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ediafena | Ferbex | Fibrolow lidose | Fibronil | Lipidil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Eliporate | Fenofibrate (ii) | Heng li le | Li Bi Fei | Li jiang zhi | Li zhi ping | Lipanthyl | Lipilfen | Lipilo | Rui tuo shu | Shi tai ning | Shu bei te</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fenofib | Fenofibrato | Fenolip | Lipidil | Normolip | Nortricol | Tenactan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo feno | Febira | Fenofibrat aurobindo | Fenofix | Fortilip | Hypolip | Lipanthyl | Lipanthyl nt | Lipanthyl S | Lipanthyl supra | Lipirex | Lipirex s | Lipohexal | Suprelip</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cil | Durafenat | Durafenat mf | Feno sanorania | Fenobeta | Fenofanton | Fenofibrat | Fenofibrat al | Fenofibrat Billix | Fenofibrat CT | Fenofibrat ethypharm | Fenofibrat heumann | Fenofibrat hexal | Fenofibrat sandoz | Fenofibrate sandoz | Lipanthyl | Liperial | Lipidil | Lipidil One | Normalip pro</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Controlip | Fibreges | Gadolip | Lipidil | Normolip | Triglicer | Triglikan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Controlip | Fenofikan | Lipidil | Normolip | Nortricol | Promeral</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Grofibrat | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Arteflex | Fenolip | Finofib | Finorate | Kemifib | Lipanthyl | Lipanthyl dr | Lipanthyl supra | Lipolex | Lipomedizen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrato kern pharma | Fenofibrato pensa | Fenofibrato Ranbaxy | Fenofibrato Teva | Liparison | Secalip</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cil | Fenosup lidose | Lipanthyl | Lipanthyl penta</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fegenor | Fenofibrate Actavis | Fenofibrate Almus | Fenofibrate Alter | Fenofibrate Arrow | Fenofibrate biogaran | Fenofibrate cristers | Fenofibrate cristers pharma | Fenofibrate Dci | Fenofibrate EG | Fenofibrate EGN | Fenofibrate Fournier | Fenofibrate G Gam | Fenofibrate gnr | Fenofibrate irex | Fenofibrate ivax | Fenofibrate Merck | Fenofibrate mylan | Fenofibrate Qualimed | Fenofibrate Ranbaxy | Fenofibrate ratiopharm | Fenofibrate rpg | Fenofibrate sandoz | Fenofibrate Teva | Fenofibrate Winthrop | Fenofibrate Zydus | Lipanthyl | Livesan | Secalip</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrate kent | Fenofibrate Pliva | Fenofibrate sandoz | Fenofibrate Teva | Fenogal | Lipantil | Lipantil micro | Supralip</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Climage | Fagratyl | Fenobrat | Letomode | Lipanthyl | Lipidil | Lipidil Nt | Neo disterin | Planitrix | Zerlubron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo feno super | Apo fenofibrate | Apo-feno-micro | Lexemin | Lexemin-M | Lipanthyl | Lipanthyl penta | Lipanthyl supra | Qualipantyl | Synpid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fenolip | Tricor | Ziglip | Zigotrig</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Feno-micro | Fenobrat | Fenofibrate ratiopharm | Fenoswiss | Lipanthyl | Lipanthyl nt | Lipidil | Lipidil m | Lipidil supra | Nofibal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Evothyl | Felosma | Fenoflex | Fenolip | Fenopi | Fenosup lidose | Fibramed | Hicholfen | Hipolip | Hyperchol | Lifen | Lipanthyl | Profibrat | Trichol | Trolip | Yosenob | Zumafib</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lipantil | Lipantil micro | Lipantil supra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfeno | Feno tg | Fenobate | Fenocard | Fenocor | Fenolip | Fibral | Fibrate | Fibrofen | Fibrolip | Finate | Lipicard | Lipireg | Lotgl | Stanlip | Tg check | Tgr | Trichek | Trifeno | Trilo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrato Doc | Fenofibrato eg | Fenofibrato sandoz | Fenofibrato Teva | Fenolibs | Fulcro | Fulcrosupra | Lipanthyl | Liperial | Lipofene | Lipsin | Nolipax | Tilene</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fastikol | Lipanthyl | Trigless</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrate takeda teva | Lipantil | Lipantil grelan | Lipantil kaken | Lipidil | Lipidil kaken | Tricor</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Colestrim | Fenolip | Fibral | Lipiloc</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bisron | Bisterol | Dongkoo fenofibrate | Fenfib | Fenoba | Fenobate | Fenodil | Fenofib | Fenofin | Fenofirae | Fenofiren | Fenometin | Fenopidil | Fenopy | Fenoren | Glifen sr | Glifen supreme | Glipen | Ld-low | Lipanthyl | Lipidil | Lipidil supra | Lipifeno | Lipilfen | Lipimet | Lodil | Loodil supra | Lowpirol | Lowpirol s | Myfeno | Neofeno | Nopid | Noripo | Rapidil | Redose | Ripedol | Ropandil | Rorit | Tg fenon | Tgfenon | Tizifree</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lipanthyl</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo feno super | Apo-feno-micro | Fegenor ge | Fenofibrate Arrow | Fenogal | Fenolip | Fenosup lidose | Finacor | Lipanthyl | Lipozar | Nanofib</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrat | Fenofibrat heumann | Fenofibrat sandoz | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fegenor | Fenofibrate EG | Fenogal | Lipanthyl | Lipanthylnano</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrat | Grofibrat | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Febrate | Fenogal | Fenosup lidose | Lipanthyl | Lofat</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Controlip | Controlip trilipix | Cordialibrel | Fenofibrato | Firolib | Lipidil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo fenofibrate | Apo-feno-micro | Ccm fenofibrate | Ezenol | Feno tg | Fenolip | Fenolip m | Fenosup lidose | Lexemin | Lipanthyl | Lipothin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Colestrim | Fibrotin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fenogal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrat | Fenofibrat accord | Fenofibrat ethypharm | Fenofibrat hexal | Fenofibrate impax | Lipanthyl | Lipantil micro | Lipofene | Secalip | Supralip</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Controlip | Enofibs | Fenosane | Fibrolow | Gasmoci pri | Normolip</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aforate | Audra | Berafen | Cholefen | Diafeno | Fenof | Fenofast | Fenoflex | Fenogal | Fenogen | Fenolit | Fenorate | Fibrafen 200m | Fibril | Gofibra | Lipanthyl | Lipibrate | Lipiduce | Lipway | Nubrex | Primenofast | Q dipils | Trichek | Trolip | Zinof</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cardiwel | Corfibrate | Fenocor | Fenofib | Fenoget | Fenolip | Fenomad | Fenomax | Fenrate | Liplo | Lipofen | Lipogin | Nenofeb</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo feno | Biofibrat | Fenardin | Fenofibrat | Fenoratio | Grofibrat | Grofibrat M | Grofibrat S | Lipanthyl | Lipanthyl nt | Lipanthyl supra | Xafenor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antara | Lofibra | Tricor | Triglide</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Catalip | Catalip micronizado | Fenofibrato | Fenofibrato farmoz | Fenofibrato Generis | Fenofibrato Mylan | Fenofibrato Zentiva | Lipanthyl | Lipofen | Supralip</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fenosup | Gadolip | Lipifen t.u. | Sclerofin u.d. | Sulnit | Sulnit cd</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lipanthyl | Lipanthyl Micronised | Nolip | Trigless</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fenofibrat lph | Fenofibrat terapia | Fenofibrat teva | Fenolip | Lipanthyl | Lipanthyl supra | Lipantil nano | Lipivim | Lipofib | Lipofib sr | Triglipo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Exlip | Fenofibrate canon | Lipanthyl | Lipantil | Tricor | Trilipix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-feno-micro | Fenogal Lidose | Lipanthyl | Trix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Catalip | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fenogal Lidose | Fenosup lidose | Gen-Fenofibrate | Lexemin | Lipanthyl | Trolip</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Katalip | Tricor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Febira | Fenofix | Lipanthyl | Lipanthyl nt | Lipanthyl supra | Suprelip</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Adfen 200 | Fenofibrate gpo | Fenohexal | Fenomed | Fenosup lidose | Fenox | Fibril | Fibril nt | Fibrolan | Lexemin | Lipanthyl | Lipothin | Lofibrate 160 | Stanlip | Supralip | Supralip Nt</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Antilip | Fenolip | Fenothyl | Hypolip | Lipanthyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fepatil | Lipanthyl | Lipofen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Down-Lip | Fendown | Fenofibrate ethypharm | Fenogal | Fenolip | Fenolip u | Lifenoz-U | Lipanthyl | Lipanthyl penta | Lipolin | Low-Lip | Synpid | Trilipix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lipanthyl | Lipicard | Tricor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aterolis | Gadolip | Lipiduce | Liponorm | Lipoplasmin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nortricol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Defechol | Fenbrat | Hafenthyl Supra | Lipagim | Lipidcare | Mibefen nt</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lipanthyl | Lipsin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Feno tg | Lipicard</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  AA-Feno-Micro (fenofibrate) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20228404">
<a name="20228404"></a>ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>N Engl J Med</i>. 2010;362(17):1563-1574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/20228404/pubmed" id="20228404" target="_blank">20228404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26356743">
<a name="26356743"></a>Agapakis DI, Massa EV. A case of fenofibrate-induced immune thrombocytopenia: first report. <i>P R Health Sci J</i>. 2015;34(3):170-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26356743/pubmed" id="26356743" target="_blank">26356743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29119413">
<a name="29119413"></a>Ahmad J, Odin JA, Hayashi PH, et al. Identification and characterization of fenofibrate-induced liver injury. <i>Dig Dis Sci</i>. 2017;62(12):3596-3604. doi:10.1007/s10620-017-4812-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/29119413/pubmed" id="29119413" target="_blank">29119413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15745090">
<a name="15745090"></a>Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson IM. Fenofibrate-induced cirrhosis. <i>Dig Dis Sci</i>. 2005;50(2):312-313. doi:10.1007/s10620-005-1600-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/15745090/pubmed" id="15745090" target="_blank">15745090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15464682">
<a name="15464682"></a>Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. <i>Am J Cardiol</i>. 2004;94(7):935-938. doi:10.1016/j.amjcard.2004.06.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/15464682/pubmed" id="15464682" target="_blank">15464682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21917557">
<a name="21917557"></a>Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. <i>Ann Pharmacother</i>. 2011;45(10):1230-1239. doi:10.1345/aph.1Q110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/21917557/pubmed" id="21917557" target="_blank">21917557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antara.1">
<a name="Antara.1"></a>Antara (fenofibrate) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23820458">
<a name="23820458"></a>Attridge RL, Frei CR, Ryan L, Koeller J, Linn WD. Fenofibrate-associated nephrotoxicity: a review of current evidence. <i>Am J Health Syst Pharm</i>. 2013;70(14):1219-1225. doi:10.2146/ajhp120131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/23820458/pubmed" id="23820458" target="_blank">23820458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22264570">
<a name="22264570"></a>Attridge RL, Linn WD, Ryan L, Koeller J, Frei CR. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>J Clin Lipidol</i>. 2012;6(1):19-26. doi:10.1016/j.jacl.2011.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22264570/pubmed" id="22264570" target="_blank">22264570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19741526">
<a name="19741526"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi:10.1097/MOL.0b013e3283319127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19741526/pubmed" id="19741526" target="_blank">19741526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(9):2969-2989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20486848">
<a name="20486848"></a>Buyukhatipoglu H, Sezen Y, Guntekin U, Kirhan I, Dag OF. Acute renal failure with the combined use of rosuvastatin and fenofibrate. <i>Ren Fail</i>. 2010;32(5):633-635. doi:10.3109/08860221003759452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/20486848/pubmed" id="20486848" target="_blank">20486848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30308533">
<a name="30308533"></a>Chung EK, Lee JH, Jang DK, et al. Causative agents of drug-induced pancreatitis: a nationwide assessment. <i>Pancreas</i>. 2018;47(10):1328-1336. doi:10.1097/MPA.0000000000001152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/30308533/pubmed" id="30308533" target="_blank">30308533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20811485">
<a name="20811485"></a>Danis R, Akbulut S, Ozmen S, Arikan S. Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. <i>Case Rep Med</i>. 2010;2010:537818. doi:10.1155/2010/537818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/20811485/pubmed" id="20811485" target="_blank">20811485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368275">
<a name="17368275"></a>Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. <i>Am J Cardiol</i>. 2007;99(6A):3C-18C. doi:10.1016/j.amjcard.2006.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/17368275/pubmed" id="17368275" target="_blank">17368275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7110477">
<a name="7110477"></a>Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. <i>Nephron</i>. 1982;31(1):51-54. doi:10.1159/000182614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/7110477/pubmed" id="7110477" target="_blank">7110477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16437706">
<a name="16437706"></a>Dohmen K, Wen CY, Nagaoka S, et al. Fenofibrate-induced liver injury. <i>World J Gastroenterol</i>. 2005;11(48):7702-7703. doi:10.3748/wjg.v11.i48.7702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/16437706/pubmed" id="16437706" target="_blank">16437706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23957710">
<a name="23957710"></a>Douros A, Bronder E, Andersohn F, et al. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases. <i>Aliment Pharmacol Ther</i>. 2013;38(7):825-834. doi:10.1111/apt.12461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/23957710/pubmed" id="23957710" target="_blank">23957710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32582345">
<a name="32582345"></a>Emami F, Hariri A, Matinfar M, Nematbakhsh M. Fenofibrate-induced renal dysfunction, yes or no? <i>J Res Med Sci</i>. 2020;25:39. doi:10.4103/jrms.JRMS_772_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/32582345/pubmed" id="32582345" target="_blank">32582345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22019952">
<a name="22019952"></a>Erdur FM, Soyoral YU, Emre H, Begenik H, Canbaz ET, Erkoc R. Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. <i>Clin Biochem</i>. 2012;45(1-2):162-164. doi:10.1016/j.clinbiochem.2011.09.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22019952/pubmed" id="22019952" target="_blank">22019952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference">
                  Fenofibrate capsules [prescribing information]. Weston, FL: Apotex Corp; June 2021.</div>
</li>
<li>
<div class="reference">
                  Fenofibrate capsules, USP [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; September 2021.</div>
</li>
<li>
<div class="reference">
                  Fenofibrate tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; February 2021.</div>
</li>
<li>
<div class="reference">
                  Fenoglide (fenofibric acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; June 2021.</div>
</li>
<li>
<div class="reference">
                  Fibricor (fenofibrate) tablets [prescribing information]. Athens, GA: Athena Bioscience LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575126">
<a name="30575126"></a>Gosho M. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. <i>Fundam Clin Pharmacol</i>. 2019;33(3):339-346. doi:10.1111/fcp.12435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/30575126/pubmed" id="30575126" target="_blank">30575126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19744016">
<a name="19744016"></a>Hajdu D, Aiglová K, Vinklerová I, Urbánek K. Acute cholestatic hepatitis induced by fenofibrate. <i>J Clin Pharm Ther</i>. 2009;34(5):599-602. doi:10.1111/j.1365-2710.2009.01029.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19744016/pubmed" id="19744016" target="_blank">19744016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34325660">
<a name="34325660"></a>He Y, Qin MZ, Chen YW. Liver injury caused by fenofibrate within 48 h after first administration: a case report. <i>BMC Gastroenterol</i>. 2021;21(1):298. doi:10.1186/s12876-021-01874-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/34325660/pubmed" id="34325660" target="_blank">34325660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18157972">
<a name="18157972"></a>Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. <i>Am J Cardiol</i>. 2008;101(1):95-97. doi:10.1016/j.amjcard.2007.07.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/18157972/pubmed" id="18157972" target="_blank">18157972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24500153">
<a name="24500153"></a>Innis SM. Impact of maternal diet on human milk composition and neurological development of infants. <i>Am J Clin Nutr</i>. 2014;99(3):734S-741S. doi:10.3945/ajcn.113.072595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/24500153/pubmed" id="24500153" target="_blank">24500153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15941707">
<a name="15941707"></a>Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. <i>Ann Intern Med</i>. 2005;142(11):949-950. doi:10.7326/0003-4819-142-11-200506070-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/15941707/pubmed" id="15941707" target="_blank">15941707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>J Clin Lipidol</i>. 2015;9(6)(suppl):S1-S122.e1. doi:10.1016/j.jacl.2015.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15619408">
<a name="15619408"></a>Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. <i>Am J Cardiol</i>. 2005;95(1):120-122. doi:10.1016/j.amjcard.2004.08.076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/15619408/pubmed" id="15619408" target="_blank">15619408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30666843">
<a name="30666843"></a>Kang MG, Sohn KH, Kang DY, et al. Analysis of individual case safety reports of severe cutaneous adverse reactions in Korea. <i>Yonsei Med J</i>. 2019;60(2):208-215. doi:10.3349/ymj.2019.60.2.208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/30666843/pubmed" id="30666843" target="_blank">30666843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21960954">
<a name="21960954"></a>Kato K, Nagase A, Matsuda M, et al. Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia. <i>Case Rep Gastroenterol</i>. 2011;5(2):492-496. doi:10.1159/000331559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/21960954/pubmed" id="21960954" target="_blank">21960954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16310551">
<a name="16310551"></a>Keech A, Simes RJ, Barter P, et al. Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 People With Type 2 Diabetes Mellitus (The FIELD Study): Randomised Controlled Trial. <i>Lancet</i>. 2005;366(9500):1849-1861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/16310551/pubmed" id="16310551" target="_blank">16310551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28775808">
<a name="28775808"></a>Kim S, Ko K, Park S, Lee DR, Lee J. Effect of fenofibrate medication on renal function. <i>Korean J Fam Med</i>. 2017;38(4):192-198. doi:10.4082/kjfm.2017.38.4.192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/28775808/pubmed" id="28775808" target="_blank">28775808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23833382">
<a name="23833382"></a>Kiskac M, Zorlu M, Cakirca M, et al. A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report. <i>Indian J Pharmacol</i>. 2013;45(3):305-306. doi:10.4103/0253-7613.111912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/23833382/pubmed" id="23833382" target="_blank">23833382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23480615">
<a name="23480615"></a>Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. <i>Eur J Clin Invest</i>. 2013;43(5):522-531. doi:10.1111/eci.12068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/23480615/pubmed" id="23480615" target="_blank">23480615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33704429">
<a name="33704429"></a>Li X, Sun W, Lu J, et al. Effects of fenofibrate therapy on renal function in primary gout patients. <i>Rheumatology (Oxford)</i>. 2021;60(11):5020-5027. doi:10.1093/rheumatology/keab231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/33704429/pubmed" id="33704429" target="_blank">33704429</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lipidil EZ (fenofibrate) tablets [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; February 2021.</div>
</li>
<li>
<div class="reference">
                  Lipidil Supra (fenofibrate) tablets [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma; January 2017.</div>
</li>
<li>
<div class="reference">
                  Lipofen (fenofibrate) capsules [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28474616">
<a name="28474616"></a>Loh TY, Cohen PR. Ketoprofen-induced photoallergic dermatitis. <i>Indian J Med Res</i>. 2016;144(6):803-806. doi:10.4103/ijmr.IJMR_626_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/28474616/pubmed" id="28474616" target="_blank">28474616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16937543">
<a name="16937543"></a>Lucena MI, Andrade RJ, Vicioso L, González FJ, Pachkoria K, García-Muñoz B. Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World J Gastroenterol</i>. 2006;12(32):5244-5246. doi:10.3748/wjg.v12.i32.5244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/16937543/pubmed" id="16937543" target="_blank">16937543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31518450">
<a name="31518450"></a>Ma S, Liu S, Wang Q, Chen L, Yang P, Sun H. Fenofibrate-induced hepatotoxicity: a case with a special feature that is different from those in the LiverTox database. <i>J Clin Pharm Ther</i>. 2020;45(1):204-207. doi:10.1111/jcpt.13042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/31518450/pubmed" id="31518450" target="_blank">31518450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32540810">
<a name="32540810"></a>Matsuda KM, Tanaka-Mizutsugu H, Kishi Y, Hino H, Kagami S. A case of lichenoid drug eruption induced by fenofibrate. <i>Eur J Dermatol</i>. 2020;30(3):308-309. doi:10.1684/ejd.2020.3780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/32540810/pubmed" id="32540810" target="_blank">32540810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29282398">
<a name="29282398"></a>Mohammed F, Wally LL, Karaban JE, Reddy VB, Lertratanakul Y. Fenofibrate-induced lichenoid drug eruption: a rare culprit. <i>Case Rep Dermatol</i>. 2017;9(3):236-242. doi:10.1159/000484471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/29282398/pubmed" id="29282398" target="_blank">29282398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morais.1">
<a name="Morais.1"></a>Morais P, Barros AM, Cunha AP, Azevedo F. Fenofibrate-induced acute generalized exanthematous pustulosis. <i>Egyptian Dermatology Online Journal</i>. 2008;4(2).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22432114">
<a name="22432114"></a>Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. <i>Diabetes Care</i>. 2012;35(5):1008-1014. doi:10.2337/dc11-1811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22432114/pubmed" id="22432114" target="_blank">22432114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19403838">
<a name="19403838"></a>Mymin D, Dembinski T, Friesen MH. Iatrogenic severe depression of high-density lipoprotein cholesterol. <i>J Clin Pharmacol</i>. 2009;49(7):865-871. doi:10.1177/0091270009335766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19403838/pubmed" id="19403838" target="_blank">19403838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed November 16, 2021. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference">
                  National Institute for Health and Care Excellence (2008) Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NICE. (Clinical Guideline 71).Available at http://www.nice.org.uk/CG71.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28043905">
<a name="28043905"></a>Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. <i>Gastroenterology</i>. 2017;152(5):1078-1089. doi:10.1053/j.gastro.2016.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/28043905/pubmed" id="28043905" target="_blank">28043905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22812208">
<a name="22812208"></a>Pecora V, Nucera E, Aruanno A, Buonomo A, Schiavino D. Delayed-type hypersensitivity to fenofibrate. <i>J Investig Allergol Clin Immunol</i>. 2012;22(4):304-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/22812208/pubmed" id="22812208" target="_blank">22812208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26581932">
<a name="26581932"></a>Power AE, Graudins LV, McLean CA, Hopper I. Probable fenofibrate-induced acute generalized exanthematous pustulosis. <i>Am J Health Syst Pharm</i>. 2015;72(23):2061-2063. doi:10.2146/ajhp150171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26581932/pubmed" id="26581932" target="_blank">26581932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11240449">
<a name="11240449"></a>Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L. Rare side-effects of fenofibrate. <i>Diabetes Metab</i>. 2001;27(1):66-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/11240449/pubmed" id="11240449" target="_blank">11240449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25269143">
<a name="25269143"></a>Safrano L, Bourneau-Martin D, Le Clech C, et al. Suspicion of fenofibrate-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report. <i>Therapie</i>. 2014;69(5):461-464. doi:10.2515/therapie/2014054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/25269143/pubmed" id="25269143" target="_blank">25269143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1430357">
<a name="1430357"></a>Serrano G, Fortea JM, Latasa JM, et al. Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. <i>J Am Acad Dermatol</i>. 1992;27(2, pt 1):204-208. doi:10.1016/0190-9622(92)70171-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/1430357/pubmed" id="1430357" target="_blank">1430357</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi:10.1161/01.cir.0000437738.63853.7a</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17994463">
<a name="17994463"></a>Tahmaz M, Kumbasar B, Ergen K, Ure U, Karatemiz G, Kazancioglu R. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. <i>Ren Fail</i>. 2007;29(7):927-930. doi:10.1080/08860220701573640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/17994463/pubmed" id="17994463" target="_blank">17994463</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tricor (fenofibrate) tablets [prescribing information]. North Chicago, IL: AbbVie Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Triglide (fenofibric acid) [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; June 2021.</div>
</li>
<li>
<div class="reference">
                  Trilipix (fenofibric acid) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28317179">
<a name="28317179"></a>Tsai KC, Yang JH, Hung SJ. Fenofibrate-induced photosensitivity - a case series and literature review. <i>Photodermatol Photoimmunol Photomed</i>. 2017;33(4):213-219. doi:10.1111/phpp.12305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/28317179/pubmed" id="28317179" target="_blank">28317179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18520113">
<a name="18520113"></a>Unal A, Torun E, Sipahioglu MH, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. <i>Intern Med</i>. 2008;47(11):1017-1019. doi:10.2169/internalmedicine.47.0939<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/18520113/pubmed" id="18520113" target="_blank">18520113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34332805">
<a name="34332805"></a>Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/34332805/pubmed" id="34332805" target="_blank">34332805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620657">
<a name="29620657"></a>Wang D, Wang Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. <i>Medicine (Baltimore)</i>. 2018;97(14):e0318. doi:10.1097/MD.0000000000010318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/29620657/pubmed" id="29620657" target="_blank">29620657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512474">
<a name="27512474"></a>Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: A practical approach for clinicians. <i>Obstet Med</i>. 2015;8(4):158-167. doi:10.1177/1753495X15594082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/27512474/pubmed" id="27512474" target="_blank">27512474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30911397">
<a name="30911397"></a>Wong SX, Tham MY, Goh CL, Cheong HH, Chan SY. Spontaneous cutaneous adverse drug reaction reports-an analysis of a 10-year dataset in Singapore. <i>Pharmacol Res Perspect</i>. 2019;7(2):e00469. doi:10.1002/prp2.469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/30911397/pubmed" id="30911397" target="_blank">30911397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19756555">
<a name="19756555"></a>Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. <i>Eur J Clin Pharmacol</i>. 2009;65(12):1169-1174. doi:10.1007/s00228-009-0723-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/19756555/pubmed" id="19756555" target="_blank">19756555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32481339">
<a name="32481339"></a>Zhou J, Li D, Cheng Q. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: a rare case report and a review of the literature. <i>Medicine (Baltimore)</i>. 2020;99(21):e20390. doi:10.1097/MD.0000000000020390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fenofibrate-drug-information/abstract-text/32481339/pubmed" id="32481339" target="_blank">32481339</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 91482 Version 675.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
